Unicycive posts Q2 loss as FDA inspects OLC manufacturing site

Unicycive Therapeutics reported second-quarter 2026 results and said it has $61.4 million in cash, cash equivalents and marketable securities, enough to fund operations into 2027. The company is still waiting on an FDA facility inspection tied to its lead kidney-disease drug, oxylanthanum carbonate, after a second complete response letter in June.

Why it matters: - Unicycive’s lead program, oxylanthanum carbonate, remains its clearest path to a commercial launch in kidney disease. - The company said it had $61.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, with expected runway into 2027. - The FDA inspection assignment is the next key step before Unicycive can try to resubmit the NDA.

What happened: - Unicycive Therapeutics reported second-quarter 2026 financial results and a business update on Aug. 12, 2026. - The company received a Complete Response Letter in June for the resubmitted NDA for oxylanthanum carbonate, or OLC, for hyperphosphatemia in patients with chronic kidney disease on dialysis. - The CRL cited the same third-party manufacturing deficiencies identified in the June 2025 CRL. - The FDA did not raise concerns about clinical efficacy or safety data. - The FDA did not request additional data from Unicycive. - The company said its third-party vendor received written notice that the FDA has assigned a facility inspection.

The details: - Unicycive said dialogue with the FDA on OLC labeling and packaging has been productive and continuous. - Chief Executive Officer Shalabh Gupta said the company is optimistic about a successful inspection of the third-party manufacturing facility, which would allow a prompt NDA resubmission. - Unicycive said it is advancing commercial readiness work ahead of a possible approval. - The company is focusing on patient access across reimbursement settings. - Unicycive plans to support patients through its UniSource reimbursement hub. - The company plans to meet with the patient and clinical community at several third-quarter medical meetings. - Those meetings include the 51st Annual American Association of Kidney Patients National Patient Meeting in Little Rock, Arkansas, from Sept. 11-13. - Another planned event is the 2026 Renal Healthcare Association Annual Conference in Savannah, Georgia, from Sept. 23-26.

Between the lines: - The FDA’s focus on manufacturing, rather than efficacy or safety, narrows the issue but still leaves Unicycive dependent on a third party. - The company is using the delay to build launch infrastructure, which suggests management is preparing for a possible approval while regulatory timing remains uncertain. - The continued push into reimbursement support signals that Unicycive is trying to reduce friction for patients and prescribers if OLC clears review.

What's next: - Unicycive plans to update investors after the FDA inspection is completed. - A successful inspection could clear the way for another NDA resubmission for OLC. - The company will continue meeting with kidney-disease stakeholders during the third quarter.

The bottom line: - Unicycive has enough cash to keep operating into 2027, but OLC’s path to approval still hinges on fixing third-party manufacturing issues.